Biogen Drops on Doctor Worry Over Drug Class Including Tecfidera

Biogen Inc. shares sank after doctors in a top medical journal said more instances of brain infections may occur in people taking a type of medication that includes the drugmaker’s top-selling multiple sclerosis treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.